{"name": "Ambit Biosciences",
 "permalink": "ambit-biosciences",
 "crunchbase_url": "http://www.crunchbase.com/company/ambit-biosciences",
 "homepage_url": "http://www.ambitbio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2000,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "sales@ambitbio.com",
 "phone_number": "858-334-2100",
 "description": "",
 "created_at": "Sat Jun 11 02:24:09 UTC 2011",
 "updated_at": "Fri Mar 22 17:43:17 UTC 2013",
 "overview": "\u003Cp\u003EAmbit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit\u0026#8217;s lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML.  Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.  In addition to AC220, Ambit\u0026#8217;s clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor.  Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[95,
       108],
      "assets/images/resized/0013/8681/138681v1-max-150x150.png"],
     [[95,
       108],
      "assets/images/resized/0013/8681/138681v1-max-250x250.png"],
     [[95,
       108],
      "assets/images/resized/0013/8681/138681v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Alan",
      "last_name": "Lewis",
      "permalink": "alan-lewis-2",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Alan",
      "last_name": "Fuhrman",
      "permalink": "alan-fuhrman",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Christopher",
      "last_name": "J. Morl",
      "permalink": "christopher-j-morl",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$80M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.ambitbio.com/news/press_061011.htm",
    "source_description": "AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 6,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Apposite Capital",
         "permalink": "apposite-capital",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/8877/48877v2-max-150x150.png"],
             [[250,
               86],
              "assets/images/resized/0004/8877/48877v2-max-250x250.png"],
             [[261,
               90],
              "assets/images/resized/0004/8877/48877v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "OrbiMed Advisors",
         "permalink": "orbimed-advisors",
         "image":
          {"available_sizes":
            [[[150,
               42],
              "assets/images/resized/0005/0248/50248v1-max-150x150.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-250x250.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Forward Ventures",
         "permalink": "forward-ventures",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/9546/49546v1-max-150x150.png"],
             [[250,
               33],
              "assets/images/resized/0004/9546/49546v1-max-250x250.png"],
             [[384,
               52],
              "assets/images/resized/0004/9546/49546v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Roche Venture Fund",
         "permalink": "roche-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0004/6088/46088v1-max-150x150.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-250x250.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MedImmune Ventures",
         "permalink": "medimmune-ventures",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0004/9449/49449v2-max-150x150.jpg"],
             [[250,
               31],
              "assets/images/resized/0004/9449/49449v2-max-250x250.jpg"],
             [[450,
               57],
              "assets/images/resized/0004/9449/49449v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Gimv",
         "permalink": "gimv",
         "image":
          {"available_sizes":
            [[[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-150x150.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-250x250.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GrowthWorks Capital",
         "permalink": "growthworks",
         "image":
          {"available_sizes":
            [[[150,
               38],
              "assets/images/resized/0002/8728/28728v1-max-150x150.png"],
             [[187,
               48],
              "assets/images/resized/0002/8728/28728v1-max-250x250.png"],
             [[187,
               48],
              "assets/images/resized/0002/8728/28728v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Radius Ventures",
         "permalink": "radius-ventures",
         "image":
          {"available_sizes":
            [[[150,
               61],
              "assets/images/resized/0010/3113/103113v3-max-150x150.png"],
             [[167,
               68],
              "assets/images/resized/0010/3113/103113v3-max-250x250.png"],
             [[167,
               68],
              "assets/images/resized/0010/3113/103113v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "NovaQuest",
         "permalink": "novaquest",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0025/8138/258138v1-max-150x150.png"],
             [[204,
               47],
              "assets/images/resized/0025/8138/258138v1-max-250x250.png"],
             [[204,
               47],
              "assets/images/resized/0025/8138/258138v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Horizon Technology Finance Management LLC",
         "permalink": "horizon-technology-finance",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0003/5674/35674v2-max-150x150.png"],
             [[250,
               52],
              "assets/images/resized/0003/5674/35674v2-max-250x250.png"],
             [[259,
               54],
              "assets/images/resized/0003/5674/35674v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://finance.yahoo.com/news/ambit-biosciences-completes-50-million-130000590.html",
    "source_description": "Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia",
    "raised_amount": 50000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 11,
    "funded_day": 6,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "OrbiMed Advisors",
         "permalink": "orbimed-advisors",
         "image":
          {"available_sizes":
            [[[150,
               42],
              "assets/images/resized/0005/0248/50248v1-max-150x150.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-250x250.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Aisling Capital",
         "permalink": "aisling-capital",
         "image":
          {"available_sizes":
            [[[150,
               56],
              "assets/images/resized/0004/6625/46625v1-max-150x150.png"],
             [[159,
               60],
              "assets/images/resized/0004/6625/46625v1-max-250x250.png"],
             [[159,
               60],
              "assets/images/resized/0004/6625/46625v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Apposite Capital",
         "permalink": "apposite-capital",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0004/8877/48877v2-max-150x150.png"],
             [[250,
               86],
              "assets/images/resized/0004/8877/48877v2-max-250x250.png"],
             [[261,
               90],
              "assets/images/resized/0004/8877/48877v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Roche Venture Fund",
         "permalink": "roche-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0004/6088/46088v1-max-150x150.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-250x250.jpg"],
             [[156,
               22],
              "assets/images/resized/0004/6088/46088v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GrowthWorks Capital",
         "permalink": "growthworks",
         "image":
          {"available_sizes":
            [[[150,
               38],
              "assets/images/resized/0002/8728/28728v1-max-150x150.png"],
             [[187,
               48],
              "assets/images/resized/0002/8728/28728v1-max-250x250.png"],
             [[187,
               48],
              "assets/images/resized/0002/8728/28728v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MedImmune Ventures",
         "permalink": "medimmune-ventures",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0004/9449/49449v2-max-150x150.jpg"],
             [[250,
               31],
              "assets/images/resized/0004/9449/49449v2-max-250x250.jpg"],
             [[450,
               57],
              "assets/images/resized/0004/9449/49449v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Forward Ventures",
         "permalink": "forward-ventures",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/9546/49546v1-max-150x150.png"],
             [[250,
               33],
              "assets/images/resized/0004/9546/49546v1-max-250x250.png"],
             [[384,
               52],
              "assets/images/resized/0004/9546/49546v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Gimv",
         "permalink": "gimv",
         "image":
          {"available_sizes":
            [[[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-150x150.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-250x250.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Radius Ventures",
         "permalink": "radius-ventures",
         "image":
          {"available_sizes":
            [[[150,
               61],
              "assets/images/resized/0010/3113/103113v3-max-150x150.png"],
             [[167,
               68],
              "assets/images/resized/0010/3113/103113v3-max-250x250.png"],
             [[167,
               68],
              "assets/images/resized/0010/3113/103113v3-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "4215 Sorrento Valley Blvd.",
    "address2": "",
    "zip_code": "92121",
    "city": "San Diego",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}